| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:JS25
CAS:2411771-95-2
Package:100mg/RMB 19500;25mg/RMB 11700;50mg/RMB 15300
|
2-Propenamide, N-[3-methyl-5-[8-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- manufacturers
- JS25
-
- $2800.00 / 100mg
-
2025-10-27
- CAS:2411771-95-2
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2-Propenamide, N-[3-methyl-5-[8-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- Basic information |
| | 2-Propenamide, N-[3-methyl-5-[8-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- Chemical Properties |
| density | 1.397±0.06 g/cm3(Predicted) | | pka | 7.95±0.10(Predicted) | | form | Solid | | color | Light yellow to light brown |
| | 2-Propenamide, N-[3-methyl-5-[8-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- Usage And Synthesis |
| Uses | JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier[1]. | | in vivo | JS25 (10 mg/kg and 20 mg/kg; i.p.; every 2 days, for 14 d) inhibits tumor growth and results a significant reduction in their secondary tumor formation in murine xenograft model of Burkitt’s lymphoma[1].
JS25 (1, 2.5, and 5 μM; injection; every day for 2 days) decreases tumor burden in zebrafish patient-derived xenografts of chronic lymphocytic leukemia, wich efficacy is better than Ibrutinib.html" class="link-product" target="_blank">Ibrutinib (HY-10997)[1].
| Animal Model: | Female adult BALB/c/NSG mice with Raji cells (s.c.)[1] | | Dosage: | 10 mg/kg and 20 mg/kg | | Administration: | Intraperitoneal injection; every 2 days for 14 days | | Result: | Caused a 30-40% reduction of the subcutaneous tumor and an overall reduction in the percentage of metastasis and secondary tumor formation. |
| | References | [1] Sousa B B, et al. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors[J]. ACS Pharmacology & Translational Science, 2022. |
| | 2-Propenamide, N-[3-methyl-5-[8-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- Preparation Products And Raw materials |
|